GCA is really a chronic disease, difficult to maintain remission off meds, regardless of initial treatment strategy. Findings from Part 2 of the GIACTA trial of tocilizumab for GCA. Dr. John Stone #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/gxdQrH0pUj